Clinical Breast Cancer 

TL;DR: The relationship between level of HER2 amplification and clinical outcome will require reanalysis of pivotal trial data, and the distribution frequency of Her2 protein expression and gene amplification in invasive ductal and lobular breast cancer is provided.

TL;DR: The armamentarium of "targeted therapeutics" for triple-negative breast cancer is evolving and includes strategies to inhibit angiogenesis, epidermal growth factor receptor, and other kinases, which makes inhibition of poly(adenosine diphosphate-ribose) polymerase-1 an attractive therapeutic strategy that is in active study.

TL;DR: A review of recent breast cancer incidence and mortality statistics and why these vary so greatly across the world is reviewed.

TL;DR: The duration of first-, second-, and third-line chemotherapy as a surrogate for duration of treatment response was evaluated to identify prognostic variables and revealed that age < 50 years, ALP > 120 U/L, history of previous chemotherapy, DDFI < 12 months, and visceral presentation were all independently associated with a poor prognosis.

TL;DR: Assessment of HER2 amplification by FISH is the preferred method to select patients for trastuzumab therapy, as determined by fluorescence in situ hybridization (FISH), in women with metastatic breast cancer treated with trastizumab in 3 clinical trials.